On January 5, 2026, Novo Nordisk launched the Wegovy® pill (semaglutide) 1.5 mg starter dose—the first and only oral GLP-1 therapy approved for chronic weight management—in more than 70,000 U.S. pharmacies including CVS and Costco, as well as through telehealth providers and NovoCare® Pharmacy. In the 64-week OASIS 4 Phase 3 trial, once-daily Wegovy® tablets delivered an average weight reduction of 16.6% if all patients stayed on treatment, and 13.6% regardless of treatment adherence, compared with 2.7% and 2.4% for placebo, respectively. The self-pay price for the starter dose is set at $149 per month, rising to $199 after April 15 for the 4 mg dose and $299 for higher doses; insured patients pay as little as $25 monthly under the company’s savings offer.

WW International has added the oral Wegovy® formulation to its Med+ program, leveraging its NovoCare® Recognized Care Provider status to pair once-daily GLP-1 therapy with behavioral science, physician oversight and digital tools. In real-world data from the GLP-1 Success Program, members prescribed a GLP-1 who engaged regularly with Weight Watchers lost 61.3% more body weight at one month and 29.1% more at twelve months than peers using medication alone. The program’s $149-per-month self-pay offer for the Wegovy® pill aims to broaden access and improve adherence by integrating clinical care, structured coaching and community support.

RedHill Biopharma is developing RHB-102, a once-daily extended-release ondansetron tablet, to mitigate gastrointestinal side effects—nausea, vomiting and diarrhea—that drive up to 50% of early discontinuations in GLP-1/GIP agonist therapies such as Ozempic® and Wegovy®. Supported by positive Phase 3 data in gastroenteritis and Phase 2 results in IBS-D, RHB-102 is being advanced via an accelerated FDA 505(b)(2) pathway. With over 22 million annual U.S. ER prescriptions of ondansetron, the company plans a Phase 2 proof-of-concept trial in early 2026 and projects that reducing GI intolerance could recapture up to $35 billion in lost GLP-1 market value by 2030.

Ascletis Pharma received FDA clearance for a 13-week, randomized, double-blind, placebo-controlled Phase II study of its small-molecule GLP-1 receptor agonist ASC30 in type 2 diabetes patients, with approximately 100 participants across U.S. sites. Primary endpoints include change in HbA1c, fasting glucose and body weight; enrollment begins in Q1 2026. In a prior 13-week obesity trial, ASC30 achieved dose-dependent placebo-adjusted weight loss of 5.4%, 7.0% and 7.7% at 20 mg, 40 mg and 60 mg, respectively, with gastrointestinal tolerability comparable or superior to published profiles of competitor oral GLP-1 agents.